“…The study demonstrated that in the ERr 731 ® group, the Menopause Rating Scale II (MRS II) total score in addition to each of the 11 MRS II criteria representing cardinal symptoms of the climacteric were significantly reduced compared to the placebo group. Additionally, 82 subjects of this clinical trial continued intake of ERr 731 ® in the following 48-and 96-week open-label observational studies which demonstrated the longterm safety of ERr 731 ® , as no endometrial hyperplasia could be detected and no adverse events related to the study medication occurred [5]. However, in contrast to the clinical effectiveness of ERr 731 ® , little was known about the molecular mechanism of the extract or its potential metabolites.…”